Article Information
History
- January 29, 2017.
Article Versions
- Version 1 (August 10, 2016 - 15:05).
- Version 2 (August 14, 2016 - 17:25).
- You are viewing Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Mateusz Maciejewski, PhD1,*,
- Eugen Lounkine, PhD2,*,
- Steven Whitebread, BS2,
- Pierre Farmer, PhD3,
- Bill DuMouchel, PhD4,
- Brian K. Shoichet, PhD5,* and
- Laszlo Urban, MD, PhD2,*
- 1Pfizer, Inc. 1 Portland Street, Cambridge, MA, 02139, USA.
- 2Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA.
- 3Novartis Institutes for Biomedical Research, 4056 Basel, Switzerland.
- 4Oracle Health Sciences, Burlington, MA 01803, USA.
- 5University of California, San Francisco San Francisco, CA 94158, USA.
- ↵*Corresponding authors: Laszlo Urban, MD, PhD, Preclinical Secondary Pharmacology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA., 02139, U.S.A. e-mail: laszlo.urban{at}novartis.com; Mateusz Maciejewski, PhD, Inflammation & Immunology, Pfizer Inc., 1 Portland Street, Cambridge, MA, 02139, U.S.A. e-mail: matt{at}mattmaciejewski.com; Eugen Lounkine, PhD, Center for Proteomic Chemistry, 250 Massachusetts Avenue, Cambridge, MA., 02139, U.S.A. e-mail: eugen.lounkine{at}novartis.com; Brian K. Shoichet, PhD, Dept. of Pharmaceutical Chemistry, University of California, San Francisco, 1700 4th St., Byers Hall Suite 508D CA., 94158-2550, U.S.A. e-mail: shoichet{at}cgl.ucsf.edu